Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories.
To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
----------------------------------------------
** BREAST CANCER News **
Survival In Patients With Metastatic Breast Cancer Improved By Nonhormonal Treatment Regimens
http://www.medicalnewstoday.com/articles/132467.php
Nonhormonal treatment regimens, including anthracycline-based regimens and taxanes, have improved overall survival in women with advanced (metastatic or recurrent inoperable) breast cancer over the last 35 years, according to a systematic review published December 9 in the<i> Journal of the National Cancer Institute.
----------------------------------------------
** CANCER / ONCOLOGY News **
Curis Announces Genentech's Initiation Of Phase II Clinical Trial In Advanced Ovarian Cancer With Hedgehog Pathway Inhibitor
http://www.medicalnewstoday.com/articles/132526.php
Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation proprietary targeted medicines for cancer treatment, today announced that its collaborator Genentech has initiated a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog pathway inhibitor, as a maintenance therapy for ovarian cancer patients in second or third complete remission.
CyDex Pharmaceuticals Receives Orphan-Drug Designation For Melphalan
http://www.medicalnewstoday.com/articles/132524.php
CyDex Pharmaceuticals, Inc. today announced that it has received orphan-drug designation from the U.S. Food and Drug Administration (FDA) for melphalan "as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation.
Geron Presents Interim Clinical Data On Its Telomerase Inhibitor Drug Trial In Patients With Multiple Myeloma
http://www.medicalnewstoday.com/articles/132506.php
Geron Corporation (Nasdaq:GERN) today announced the presentation of interim data at the 2008 meeting of the American Society of Hematology in San Francisco, CA, for its ongoing clinical trial of GRN163L, a telomerase inhibitor drug, in patients with relapsed and refractory multiple myeloma.
Cancer Deaths To Double Over Next Two Decades
http://www.medicalnewstoday.com/articles/132500.php
Tobacco use and the spread of Westernized lifestyles are the two main factors pushing up cancer death figures in developing countries globally, according to a new report issued by <a href="http://www.
CAL-101, An Oral P110δ Isoform-Selective PI3 Kinase Inhibitor, Demonstrates Preclinical Activity In Hematologic Cancer Cells
http://www.medicalnewstoday.com/articles/132494.php
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective PI3 kinase inhibitors for the treatment of cancer and inflammatory diseases, today announced the presentation of data demonstrating that the Company's oral, p110δ(delta) selective PI3 kinase inhibitor CAL-101 has broad preclinical anti-tumor activity against a range of hematologic malignancies.
Landmark Analysis Shows Continuous Treatment With REVLIMID(R) Plus Dexamethasone Significantly Increases Overall Survival In Multiple Myeloma Patients
http://www.medicalnewstoday.com/articles/132493.php
Celgene International SÃ rl (NASDAQ: CELG) announced that data from a landmark analysis of patients with relapsed/refractory multiple myeloma found that continuous treatment with REVLIMID (lenalidomide) in combination with dexamethasone after achieving best response resulted in significantly longer overall survival and increased time to disease progression compared to those who discontinued treatment after ten months or less.
GPC Biotech Opens Enrollment In Phase 1 Trial Evaluating RGB-286638 Multi-Targeted Protein Kinase Inhibitor In Patients With Advanced Solid Tumors
http://www.medicalnewstoday.com/articles/132486.php
GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today announced that enrollment has opened in a Phase 1 study evaluating RGB-286638 in patients with advanced solid tumors. This is the first time that this novel drug candidate is being studied in human clinical trials.
Radon Causes 100 Times More Deaths Than Carbon Monoxide Poisoning - EPA Launches National Radon Action Month
http://www.medicalnewstoday.com/articles/132483.php
Jamey J. Gelina, President of Air Quality Control, the Nation's largest radon gas mitigation and engineering agency is reminding the media that National Radon Action Monthis quickly approaching.
Mutation In Bone Marrow Cancers Blocked By Promising New Drug , May Also Help Patients With Rheumatoid Arthritis
http://www.medicalnewstoday.com/articles/132473.php
Oregon Health & Science University Knight Cancer Institute researchers have found that an experimental drug successfully blocks an enzyme that causes some bone marrow cancers.The oral drug, called CYT387, was tested in mice as well as in human cells.
News From The Journal Of The National Cancer Institute, Dec. 9
http://www.medicalnewstoday.com/articles/132470.php
<b>Age-Related Crossover in Breast Cancer Incidence Between Black and White Ethnic Groups Appears Robust</b>Among women younger than 40 years, black women have a higher incidence of breast cancer than white women.
The Economic Cost Of Cancer Mortality Is High In The US, Regardless Of How Cost Is Measured
http://www.medicalnewstoday.com/articles/132468.php
The economic cost of death due to cancer is high in the United States, regardless of whether researchers estimate the economic impact in lost work productivity or in a more global measure using the value of one year of life, according to two studies published online December 9 in the <i>Journal of the National Cancer Institute.
Vitamin C Or E Supplementation Not Associated With Reduced Risk Of Prostate Or Other Cancers
http://www.medicalnewstoday.com/articles/132410.php
Long-term supplementation with either vitamin E or vitamin C does not appear to reduce the risk of prostate cancer or other cancers, according to a study released on early December 9, 2008 Online in <i>JAMA</i>.
Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials Of Carfilzomib In Multiple Myeloma At The 50th Annual Meeting
http://www.medicalnewstoday.com/articles/132389.php
Proteolix, Inc. announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma.
----------------------------------------------
** CERVICAL CANCER / HPV VACCINE News **
No news for this category today.
----------------------------------------------
** COLORECTAL CANCER News **
No news for this category today.
----------------------------------------------
** LUNG CANCER News **
No news for this category today.
----------------------------------------------
** LYMPHOMA / LEUKEMIA News **
Clinical Studies Identify Oral Drug As Promising Future Treatment For Patients With Rare Subtype Of Non-Hodgkin Lymphoma
http://www.medicalnewstoday.com/articles/132539.php
Lenalidomide, an oral drug targeting the immune system, appears to have promise as a novel future treatment for patients with relapsed or refractory mantle-cell lymphoma, according to a study led by <a href="http://www.
ZIOPHARM Presents Positive Darinaparsin Phase II Data At ASH Meeting
http://www.medicalnewstoday.com/articles/132527.php
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that on December 6th it presented positive data from a Phase II study of darinaparsin (ZinaparTM) for the treatment of advanced lymphomas at the 50th American Society of Hematology (ASH) Annual Meeting held in San Francisco, CA.
Intense Chemotherapy Wards Off Recurrence In Half Of Mantle Cell Lymphoma Patients After Seven Years
http://www.medicalnewstoday.com/articles/132511.php
More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M.
Dangerous Side Effect For Lymphoma Patients Prevented By New Therapy
http://www.medicalnewstoday.com/articles/132509.php
Patients respond well to a new three-drug combination for indolent B cell lymphoma that also spares them prolonged, potentially lethal, suppression of blood production in the bone marrow, researchers at The University of Texas M.
ChemGenex's Omacetaxine Demonstrates 80% Complete Hematological Response Rate In Drug-Resistant CML Patients With The T315I Mutation
http://www.medicalnewstoday.com/articles/132501.php
ChemGenex Pharmaceuticals (ASX: CXS) (NASDAQ: CXSP) announced today positive interim clinical data from 44 patients enrolled in its ongoing phase 2/3 trial of omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients with the T315I mutation.
VIDAZA(R) AZA-001 Study Reports Unprecedented Survival Benefit In Higher-Risk MDS Extends To AML Patients
http://www.medicalnewstoday.com/articles/132490.php
Celgene International SÃ rl (NASDAQ: CELG) today announced results from a subset analysis of the international phase III trial (AZA-001) demonstrating that the overall survival benefit observed in higher-risk MDS patients extends to patients with acute myeloid leukemia (AML).
Dacogen(R) (decitabine For Injection) Data On Phase II Clinical Trial In Elderly Patients With Acute Myeloid Leukemia (AML)
http://www.medicalnewstoday.com/articles/132469.php
Eisai Corporation of North America today announced data from a Phase II trial evaluating a five-day dosing regimen of Dacogen® (decitabine for injection) in acute myeloid leukemia (AML), the most common form of leukemia.
----------------------------------------------
** PROSTATE / PROSTATE CANCER News **
No news for this category today.
-------------------------------------------------------------
You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
No comments:
Post a Comment